Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

 

 

Enrollment Completed in CAHptain-205 Study in Pediatric Classic Congenital Adrenal Hyperplasia (CAH)

Target Enrollment Completed in CAHmelia-203 Study in Adult Classic CAH

CAHmelia-204 Study in Adult Classic CAH on Track to Complete Enrollment in Early Q1 2024

 

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.

“Achieving completion of enrollment milestones in the CAHptain-205 and CAHmelia-203 studies underscores the strong execution of our key clinical objectives and the momentum within our adult and pediatric classic CAH programs,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences. “We continue to make notable progress in our efforts to advance tildacerfont as a potentially novel therapeutic option for people living with CAH and are eager to report topline data from CAHmelia-203 and CAHptain-205 in the first quarter of 2024.”

Recent Corporate Updates

  • CAHptain-205 Study in Pediatric Classic CAH Completes Enrollment: Enrollment in the CAHptain study is complete with 30 patients, surpassing the target enrollment of 20 patients. CAHptain is a Phase 2 open-label clinical trial that utilizes a sequential 3 cohort design (cohorts 1 and 2 comprised of adolescent patients 11 to 17 years of age, and cohort 3 comprised of children 2 to 10 years of age) to evaluate the safety, pharmacokinetics (PK), and exploratory pharmacodynamics (PD) of tildacerfont in children with classic CAH.
  • CAHmelia-203 Study in Adult Classic CAH Completes Target Enrollment: Target enrollment of 72 patients in the company’s CAHmelia-203 clinical trial is complete. CAHmelia-203 is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2b clinical trial evaluating the safety and efficacy of tildacerfont in adults with classic CAH and highly elevated levels of androstenedione (A4) at baseline while on stable glucocorticoid dosing. Due to substantial patient interest in CAHmelia-203, final enrollment in the study will exceed its original target of 72 patients.
  • CAHmelia-204 Study in Adult Classic CAH on Track to Complete Enrollment in Early Q1 2024: Enrollment in the CAHmelia-204 clinical trial surpassed 75% enrollment and remains on track to complete enrollment in the early first quarter of 2024. CAHmelia-204 is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of tildacerfont in reducing supraphysiologic glucocorticoid use in adult patients with classic CAH.

Anticipated Upcoming Milestones

  • Completion of enrollment in the ­­CAHmelia-204 clinical trial in adult classic CAH patients on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 in the early first quarter of 2024
     
  • Topline results from the CAHmelia-203 clinical trial in adult classic CAH patients with highly elevated levels of A4 in the first quarter of 2024
     
  • Topline results from all cohorts in the CAHptain-205 clinical trial in pediatric classic CAH patients in the first quarter of 2024
     
  • Topline results from the CAHmelia-204 clinical trial in adult classic CAH patients on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 in the third quarter of 2024

Third Quarter 2023 Financial Results

  • Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of September 30, 2023 were $108.0 million. Cash, cash equivalents and investments are expected to allow the company to fund operating and capital expenditures into the first half of 2025.
  • Collaboration Revenue: Collaboration revenue for the three and nine months ended September 30, 2023 were $3.1 million and $7.2 million, respectively, compared to nil for the same periods in 2022. The increase in collaboration revenue reflects the partial recognition of the $15.0 million upfront payment the company received in connection with the collaboration and license agreement with Kaken Pharmaceutical.
  • Research and Development (R&D) Expenses: R&D expenses for the three and nine months ended September 30, 2023 were $13.5 million and $38.3 million, respectively, compared to $8.8 million and $26.4 million for the same periods in 2022. The overall increase in R&D expenses was primarily related to progressing clinical development of tildacerfont in adult classic CAH, pediatric classic CAH and PCOS.
     
  • General and Administrative (G&A) Expenses: G&A expenses for the three and nine months ended September 30, 2023 were $3.2 million and $9.7 million, respectively, compared to $2.8 million and $8.8 million for the same periods in 2022.
     
  • Total Operating Expenses: Total operating expenses for the three and nine months ended September 30, 2023 were $16.7 million and $48.0 million, respectively, compared to $11.6 million and $35.2 million for the same periods in 2022.
     
  • Net Loss: Net loss for the three and nine months ended September 30, 2023 was $12.4 million and $38.0 million, respectively, compared to $11.4 million and $35.0 million for the same periods in 2022.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS). To learn more, visit www.sprucebio.com and follow us on Twitter/X @Spruce_Bio, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the enrollment, results, conduct, progress and timing of Spruce’s clinical trials; the receipt and presentation of topline data from the same; research and development plans; and Spruce’s planned operations, including its expectations regarding operating and capital expenditures being funded into the first half of 2025. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate”, “expect”, “may”, “plan”, “will”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Spruce’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Spruce undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

SPRUCE BIOSCIENCES, INC.

CONDENSED BALANCE SHEETS

(unaudited)

(in thousands, except share and per share amounts)

         

 

 

September 30,

 

December 31,

 

 

2023

 

2022

ASSETS

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

98,801

 

 

$

24,487

 

Short-term investments

 

 

9,231

 

 

 

54,590

 

Prepaid expenses

 

 

2,687

 

 

 

3,320

 

Other current assets

 

 

419

 

 

 

1,211

 

Total current assets

 

 

111,138

 

 

 

83,608

 

Right-of-use assets

 

 

1,240

 

 

 

1,400

 

Other assets

 

 

607

 

 

 

640

 

Total assets

 

$

112,985

 

 

$

85,648

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

$

3,152

 

 

$

1,426

 

Accrued expenses and other current liabilities

 

 

11,616

 

 

 

9,399

 

Term loan, current portion

 

 

1,622

 

 

 

1,622

 

Deferred revenue, current portion

 

 

7,798

 

 

 

 

Total current liabilities

 

 

24,188

 

 

 

12,447

 

Lease liabilities, net of current portion

 

 

1,083

 

 

 

1,261

 

Term loan, net of current portion

 

 

2,113

 

 

 

3,293

 

Other liabilities

 

 

220

 

 

 

161

 

Total liabilities

 

 

27,604

 

 

 

17,162

 

Commitments and contingencies

 

 

 

 

Stockholders’ equity:

 

 

 

 

Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of September 30, 2023 and December 31, 2022

 

 

 

 

 

 

Common stock, $0.0001 par value; 200,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 40,710,692 and 23,601,004 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively

 

 

4

 

 

 

3

 

Additional paid-in capital

 

 

272,662

 

 

 

218,354

 

Accumulated other comprehensive loss

 

 

(3

)

 

 

(558

)

Accumulated deficit

 

 

(187,282

)

 

 

(149,313

)

Total stockholders’ equity

 

 

85,381

 

 

 

68,486

 

Total liabilities and stockholders’ equity

 

$

112,985

 

 

$

85,648

 

SPRUCE BIOSCIENCES, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(in thousands, except share and per share amounts)

         

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2023

 

2022

 

2023

 

2022

Collaboration revenue

 

$

3,073

 

 

$

 

 

$

7,202

 

 

$

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

13,494

 

 

 

8,791

 

 

 

38,332

 

 

 

26,359

 

General and administrative

 

 

3,237

 

 

 

2,766

 

 

 

9,699

 

 

 

8,814

 

Total operating expenses

 

 

16,731

 

 

 

11,557

 

 

 

48,031

 

 

 

35,173

 

Loss from operations

 

 

(13,658

)

 

 

(11,557

)

 

 

(40,829

)

 

 

(35,173

)

Interest expense

 

 

(119

)

 

 

(110

)

 

 

(377

)

 

 

(291

)

Interest and other income, net

 

 

1,423

 

 

 

266

 

 

 

3,237

 

 

 

428

 

Net loss

 

 

(12,354

)

 

 

(11,401

)

 

 

(37,969

)

 

 

(35,036

)

Other comprehensive gain (loss), net of tax:

 

 

 

 

 

 

 

 

Unrealized gain (loss) on available for sale securities

 

 

52

 

 

 

(28

)

 

 

555

 

 

 

(689

)

Total comprehensive loss

 

$

(12,302

)

 

$

(11,429

)

 

$

(37,414

)

 

$

(35,725

)

Net loss per share, basic and diluted

 

$

(0.30

)

 

$

(0.48

)

 

$

(1.01

)

 

$

(1.49

)

Weighted-average shares of common stock outstanding,
basic and diluted

 

 

40,710,692

 

 

 

23,560,250

 

 

 

37,751,865

 

 

 

23,515,651 

 

 

Contacts

Media
Will Zasadny
Evoke Canale
(619) 961-8848
will.zasadny@evokecanale.com
media@sprucebiosciences.com

Investors
Samir Gharib
President and CFO
Spruce Biosciences
investors@sprucebiosciences.com

 
 

Source: Spruce Biosciences, Inc.

Back to news